PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 8, 20240 citationsOpen Access

Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

View Full Paper
BTBrandie C. TaylorXSXiaopeng SunPGPaula I. González-Ericsson

Key Points

Key points are not available for this paper at this time.

Abstract

Tumor growth curves for tumors with varying MHC-I loss

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Taylor et al. (2024) studied this question.

synapsesocial.com/papers/68e7b92eb6db64358770f0echttps://doi.org/10.1158/2159-8290.25191534.v1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
  2. 2Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
  3. 3Supplementary Figure 2 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
  4. 4Supplementary Figure 1 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024
  5. 5Supplementary Figure 1 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer2024